Program
asciminib
Also written as “Asciminib”, “Asciminib single agent” and “ABL001”.
Its studies are mostly in Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Leukemia, Myeloid, Chronic-Phase · Bronchiolitis Obliterans Syndrome · Renal Insufficiency, led by Novartis.
Drug pageAsciminib: every studyAll 35 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 167 open or running | phase 4since May 4, 2021 | Feb 28, 2014 | Sep 3, 2027phase 2 · NCT04925479 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 1 study since Feb 28, 2014.
- Apr 27, 2016Phase 1 study in Hepatic ImpairmentNCT02857868 · 32 enrolled · United States
- Jun 9, 2016Named asciminibINNProposed as its International Nonproprietary Name in WHO's List 115 · before, ABL001
- Mar 9, 2017Phase 3 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT03106779 · 233 enrolled · United States, Argentina, Australia and more
- Jun 15, 2018Phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT03578367 · 104 enrolled · United States, Austria, Canada and more
- Jul 20, 2018Phase 1 study in Renal InsufficiencyNCT03605277 · 14 enrolled · Bulgaria, Germany
- Dec 7, 2020Phase 3 study in Leukemia, Myeloid, Chronic-PhaseNCT04666259 · 56 enrolled · United States
- Mar 10, 2021Phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT04795427 · 84 enrolled · China
- May 4, 2021Phase 4 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT04877522 · 347 planned · United States, Argentina, Austria and more
- May 18, 2021Phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT04925479 · 46 enrolled · United States, China, France and more
- Jun 8, 20212 phase 3 studies in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT04971226, NCT04948333
- May 17, 2022Phase 2 study in Leukemia, Myeloid, Chronic-PhaseNCT05384587 · 34 enrolled · United States
- Jul 11, 2022Phase 3 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT05456191 · 568 enrolled · United States, Argentina, Bulgaria and more
- May 20, 2024Phase 4 study in Bronchiolitis Obliterans SyndromeNCT06427811 · 85 enrolled · India
- Jul 17, 2024Phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT06514534 · 20 planned · France
- Jan 15, 2026Phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT07354074 · 50 planned · United States, Australia, Brazil and more
Ahead
- Sep 3, 2027Primary completion: phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT04925479
- Feb 17, 2029Primary completion: phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT06514534
- Aug 30, 2030Primary completion: phase 4 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT04877522
- Feb 23, 2033Primary completion: phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT07354074
TargetBeta
“Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| imatinibrule | Novartis | phase 4 | 70 |
| nilotinibrule | Novartis | phase 4 | 57 |
| olverembatinibrule | Ascentage Pharma Group International | phase 3 | 10 |
| Embibatinib | Hansoh Pharmaceutical Group | phase 3 | 7 |
| TQB3911 | Sino Biopharmaceutical | phase 1 | 1 |
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07354074Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Australia, Brazil and more | 2 | Recruiting | Feb 23, 2033 | 50 |
| NCT06514534Leukemia, Myelogenous, Chronic, BCR-ABL Positive · France | 2 | Recruiting | Feb 17, 2029 | 20 |
| NCT06427811Bronchiolitis Obliterans Syndrome · India | 4 | Completed | Mar 18, 2026 | 85 |
| NCT05456191Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Argentina, Bulgaria and more | 3 | Active, not recruiting | May 15, 2025 | 568 |
| NCT05384587Leukemia, Myeloid, Chronic-Phase · United States | 2 | Active, not recruiting | Aug 13, 2025 | 34 |
| NCT04948333Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Argentina, Austria, Brazil and more | 3 | Completed | Mar 12, 2024 | 199 |
| NCT04971226Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Australia, Austria and more | 3 | Active, not recruiting | Nov 28, 2023 | 405 |
| NCT04925479Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, China, France and more | 2 | Active, not recruiting | Sep 3, 2027 | 46 |
| NCT04877522Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Argentina, Austria and more | 4 | Recruiting | Aug 30, 2030 | 347 |
| NCT04795427Leukemia, Myelogenous, Chronic, BCR-ABL Positive · China | 2 | Completed | May 29, 2023 | 84 |
| NCT04666259Leukemia, Myeloid, Chronic-Phase · United States | 3 | Completed | Jun 20, 2023 | 56 |
| NCT03605277Renal Insufficiency · Bulgaria, Germany | 1 | Completed | Mar 18, 2019 | 14 |
| NCT03578367Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Austria, Canada and more | 2 | Completed | Nov 8, 2021 | 104 |
| NCT03106779Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Argentina, Australia and more | 3 | Completed | May 25, 2020 | 233 |
| NCT02857868Hepatic Impairment · United States | 1 | Completed | Jul 20, 2017 | 32 |
| NCT02081378Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Australia, France and more | 1 | Completed | Jun 3, 2021 | 326 |
How it is read
Names in the registry
- “Asciminib”, 5 entries
- “Asciminib single agent”, 2 entries
- “ABL001”, 2 entries
- “asciminib”, 2 entries
- “Asciminib single agent pediatric formulation”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive, 11 studies
- Leukemia, Myeloid, Chronic-Phase, 2 studies
- Bronchiolitis Obliterans Syndrome, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.